Evaluation of upper gastrointestinal tract surveillance in individuals with Lynch syndrome
- Conditions
- ynch Syndrome
- Registration Number
- DRKS00031932
- Lead Sponsor
- ationales Zentrum für erbliche Tumorerkrankungen, Universitätsklinikum Bonn
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 5000
Inclusion Criteria
Signed informed consent
- Patient must be able to follow study instructions and expected to attend and complete all required study visits.
-Confirmed diagnosis of a (likely-) pathogenic germline variant in MLH1, MHS2, MSH6, PMS2 or EPCAM (Lynch Syndrome)
Exclusion Criteria
-Subjects without legal capacity who are unable to understand the nature, scope, significance and consequences of this clinical trial
- Patients with a physical or mental condition that, in the judgment of the investigator, could pose a risk to the patient, confound the study results, or interfere with participation in the clinical study
- Personal history of duodenal or gastric surgery
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative 10-year incidence of neoplasia in the upper GI tract (esophageal, gastric, duodenal and jejunum carcinomas) in patients with Lynch syndrome.<br>
- Secondary Outcome Measures
Name Time Method